Literature DB >> 22003377

Viruses - from pathogens to vaccine carriers.

Juliana C Small1, Hildegund C J Ertl.   

Abstract

Vaccination is mankind's greatest public health success story. By now vaccines to many of the viruses that once caused fatal childhood diseases are routinely used throughout the world. Traditional methods of vaccine development through inactivation or attenuation of viruses have failed for some of the most deadly human pathogens, necessitating new approaches. Genetic modification of viruses not only allows for their attenuation but also for incorporation of sequences from other viruses, turning one pathogen into a vaccine carrier for another. Recombinant viruses have pros and cons as vaccine carriers, as discussed below using vectors based on adenovirus, herpesvirus, flavivirus, and rhabdovirus as examples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003377      PMCID: PMC3190199          DOI: 10.1016/j.coviro.2011.07.009

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  36 in total

1.  Adenovirus type 11 uses CD46 as a cellular receptor.

Authors:  Anna Segerman; John P Atkinson; Marko Marttila; Veronica Dennerquist; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector.

Authors:  Daisuke Watanabe; Mark A Brockman; Thumbi Ndung'u; Lydia Mathews; William T Lucas; Cynthia G Murphy; Barbara K Felber; George N Pavlakis; Neal A Deluca; David M Knipe
Journal:  Virology       Date:  2006-09-22       Impact factor: 3.616

3.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

Authors:  Nia Tatsis; Julie C Fitzgerald; Arturo Reyes-Sandoval; Kimberly C Harris-McCoy; Scott E Hensley; Dongming Zhou; Shih-Wen Lin; Ang Bian; Zhi Quan Xiang; Amaya Iparraguirre; Cesar Lopez-Camacho; E John Wherry; Hildegund C J Ertl
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

4.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

5.  ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Authors:  Juan Arroyo; Chuck Miller; John Catalan; Gwendolyn A Myers; Marion S Ratterree; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.

Authors:  Ian D Simon; Jean Publicover; John K Rose
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

7.  Prior infection with murine cytomegalovirus (MCMV) limits the immunocontraceptive effects of an MCMV vector expressing the mouse zona-pellucida-3 protein.

Authors:  Shelley Gorman; Megan L Lloyd; Lee M Smith; Andrea R McWhorter; Malcolm A Lawson; Alec J Redwood; Geoffrey R Shellam
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

8.  The consequences of primary cytomegalovirus infection in pregnancy.

Authors:  P M Preece; J M Blount; J Glover; G M Fletcher; C S Peckham; P D Griffiths
Journal:  Arch Dis Child       Date:  1983-12       Impact factor: 3.791

9.  Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.

Authors:  Elizabeth Ramsburg; Nina F Rose; Preston A Marx; Megan Mefford; Douglas F Nixon; Walter J Moretto; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 10.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

View more
  22 in total

Review 1.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

2.  The cleaved N-terminus of pVI binds peripentonal hexons in mature adenovirus.

Authors:  Joost Snijder; Marco Benevento; Crystal L Moyer; Vijay Reddy; Glen R Nemerow; Albert J R Heck
Journal:  J Mol Biol       Date:  2014-03-05       Impact factor: 5.469

3.  Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Authors:  Susan L Baldwin; Lance K Ching; Samuel O Pine; Magdalini Moutaftsi; Elyse Lucas; Aarthy Vallur; Mark T Orr; Sylvie Bertholet; Steven G Reed; Rhea N Coler
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

Review 4.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

5.  Vaxvec: The first web-based recombinant vaccine vector database and its data analysis.

Authors:  Shunzhou Deng; Carly Martin; Rasika Patil; Felix Zhu; Bin Zhao; Zuoshuang Xiang; Yongqun He
Journal:  Vaccine       Date:  2015-09-25       Impact factor: 3.641

6.  A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.

Authors:  Rekha Dhanwani; Yanqin Zhou; Qinfeng Huang; Vikram Verma; Mythili Dileepan; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

7.  The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Authors:  Robert T Chen; Baevin Carbery; Lisa Mac; Kenneth I Berns; Louisa Chapman; Richard C Condit; Jean-Louis Excler; Marc Gurwith; Michael Hendry; Arifa S Khan; Najwa Khuri-Bulos; Bettina Klug; James S Robertson; Stephen J Seligman; Rebecca Sheets; Anna-Lise Williamson
Journal:  Vaccine       Date:  2014-10-08       Impact factor: 3.641

8.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.

Authors:  Jasdave S Chahal; Omar F Khan; Christopher L Cooper; Justine S McPartlan; Jonathan K Tsosie; Lucas D Tilley; Saima M Sidik; Sebastian Lourido; Robert Langer; Sina Bavari; Hidde L Ploegh; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

9.  VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Authors:  Reinhard Tober; Zoltan Banki; Lisa Egerer; Alexander Muik; Sandra Behmüller; Florian Kreppel; Ute Greczmiel; Annette Oxenius; Dorothee von Laer; Janine Kimpel
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 10.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.